{
    "organizations": [],
    "uuid": "c909a8b9b879cde33d61901243aacb3433a6b194",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sarepta-therapeutics-announces-pla/brief-sarepta-therapeutics-announces-plan-to-submit-a-new-drug-application-for-accelerated-approval-of-golodirsen-idUSFWN1QU0Q0",
    "ord_in_thread": 0,
    "title": "BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 12, 2018 / 11:46 AM / in 11 minutes BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen Reuters Staff 1 Min Read March 12 (Reuters) - Sarepta Therapeutics Inc: * SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53 * SAREPTA THERAPEUTICS INC - INTENDS TO COMPLETE A ROLLING SUBMISSION OF A GOLODIRSEN NDA BY YEAR-END 2018 * SAREPTA THERAPEUTICS INC - MET WITH FDA DIVISION OF NEUROLOGY PRODUCTS IN FEBRUARY TO OBTAIN GUIDANCE ON REGULATORY PATHWAY FOR GOLODIRSEN Source text for Eikon: Further company coverage:",
    "published": "2018-03-12T13:46:00.000+02:00",
    "crawled": "2018-03-12T14:04:51.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "minute",
        "therapeutic",
        "announces",
        "plan",
        "submit",
        "new",
        "drug",
        "application",
        "accelerated",
        "approval",
        "golodirsen",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "sarepta",
        "therapeutic",
        "inc",
        "sarepta",
        "therapeutic",
        "announces",
        "plan",
        "submit",
        "new",
        "drug",
        "application",
        "nda",
        "accelerated",
        "approval",
        "golodirsen",
        "patient",
        "duchenne",
        "muscular",
        "dystrophy",
        "dmd",
        "amenable",
        "skipping",
        "exon",
        "sarepta",
        "therapeutic",
        "inc",
        "intends",
        "complete",
        "rolling",
        "submission",
        "golodirsen",
        "nda",
        "sarepta",
        "therapeutic",
        "inc",
        "met",
        "fda",
        "division",
        "neurology",
        "product",
        "february",
        "obtain",
        "guidance",
        "regulatory",
        "pathway",
        "golodirsen",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}